{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:27:20Z","timestamp":1794533240710,"version":"4.9.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":238,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.prdoa.2026.100497","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:22:36Z","timestamp":1787959356000},"page":"100497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Treatment-resistant Parkinson's disease psychosis responding to xanomeline-trospium: A case report"],"prefix":"10.1016","volume":"15","author":[{"given":"Andrew","family":"Farah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Timbrook-Dillow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Garrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prdoa.2026.100497_bb0005","series-title":"COBENFY\u2122 (Xanomeline and Trospium Chloride) Capsules: Prescribing Information","author":"Bristol Myers Squibb","year":"2024"},{"key":"10.1016\/j.prdoa.2026.100497_bb0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jns.2009.08.014","article-title":"Epidemiology of psychosis in Parkinson\u2019s disease","volume":"289","author":"Fenelon","year":"2010","journal-title":"J. Neurol. Sci."},{"issue":"Suppl. 3","key":"10.1016\/j.prdoa.2026.100497_bb0015","first-page":"S42","article-title":"The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson\u2019s disease","volume":"26","author":"Seppi","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2026.100497_bb0020","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1155\/2013\/645429","article-title":"Parkinson disease psychosis: update","volume":"27","author":"Friedman","year":"2013","journal-title":"Behav. Neurol."},{"key":"10.1016\/j.prdoa.2026.100497_bb0025","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and Movement Disorder Society evidence-based medicine review","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2026.100497_bb0030","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Clozapine in drug-induced psychosis in Parkinson\u2019s disease","volume":"340","author":"Pollak","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prdoa.2026.100497_bb0035","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson\u2019s disease psychosis","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.prdoa.2026.100497_bb0040","first-page":"403","article-title":"Assessment of pimavanserin safety and efficacy in Parkinson disease psychosis","volume":"80","author":"Yunusa","year":"2023","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.prdoa.2026.100497_bb0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5152\/pcp.2024.23772","article-title":"Successful use of high-dose brexpiprazole for psychosis in Lewy body dementia without adverse effects","volume":"34","author":"Lee","year":"2024","journal-title":"Psychiatry Clin Psychopharmacol."},{"key":"10.1016\/j.prdoa.2026.100497_bb0050","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline in Alzheimer disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.prdoa.2026.100497_bb0055","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.prdoa.2026.100497_bb0060","first-page":"717","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"389","author":"Brannan","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prdoa.2026.100497_bb0065","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"EMERGENT-2 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.prdoa.2026.100497_bb0070","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial","volume":"81","author":"Kaul","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.prdoa.2026.100497_bb0075","first-page":"1024","article-title":"Allosteric modulation of M4 muscarinic receptors as a treatment strategy for psychosis","volume":"42","author":"Foster","year":"2017","journal-title":"Neuropsychopharmacology"}],"container-title":["Clinical Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112526000770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112526000770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T00:59:05Z","timestamp":1794531545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112526000770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":15,"alternative-id":["S2590112526000770"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2026.100497","relation":{},"ISSN":["2590-1125"],"issn-type":[{"value":"2590-1125","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment-resistant Parkinson's disease psychosis responding to xanomeline-trospium: A case report","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2026.100497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100497"}}